文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

探索早期临床试验中参与者多样性的障碍和重要性:基于访谈的专业人员、患者和公众代表的定性研究。

Exploring the barriers to, and importance of, participant diversity in early-phase clinical trials: an interview-based qualitative study of professionals and patient and public representatives.

机构信息

Sheffield Clinical Trials Research Unit (CTRU), Sheffield Centre for Health and Related Research, The University of Sheffield, Sheffield, UK

Sheffield Clinical Trials Research Unit (CTRU), Sheffield Centre for Health and Related Research, The University of Sheffield, Sheffield, UK.

出版信息

BMJ Open. 2024 Mar 19;14(3):e075547. doi: 10.1136/bmjopen-2023-075547.


DOI:10.1136/bmjopen-2023-075547
PMID:38508621
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10952868/
Abstract

OBJECTIVES: To explore the importance of, and barriers to achieving, diversity in early-phase clinical trials. DESIGN: Qualitative interviews analysed using thematic analysis. SETTING AND PARTICIPANTS: Five professionals (clinical researchers and methodologists) and three patient and public representatives (those with experience of early-phase clinical trials and/or those from ethnic minority backgrounds) were interviewed between June and August 2022. Participants were identified via their institutional web page, existing contacts or social media (eg, X, formerly known as Twitter). RESULTS: Professionals viewed that diversity is not currently considered in all early-phase clinical trials but felt that it should always be taken into account. Such trials are primarily undertaken at a small number of centres, thus limiting the populations they can access. Referrals from clinicians based in the community may increase diversity; however, those referred are often not from underserved groups. Referrals may be hindered by the extra resources required to approach and recruit underserved groups and participants often having to undertake 'self-driven' referrals. Patient and public representatives stated that diversity is important in research staff and that potential participants should be informed of the need for diversity. Those from underserved groups may require clarification regarding the potential harms of a treatment, even if these are unknown. Education may improve awareness and perception of early-phase clinical trials. We provide 14 recommendations to improve diversity in early-phase clinical trials. CONCLUSIONS: Diversity should be considered in all early-phase trials. Consideration is required regarding the extent of diversity and how it is addressed. The increased resources needed to recruit those from underserved groups may warrant funders to increase the funds to support the recruitment of such participants. The potential harms and societal benefits of the research should be presented to potential participants in a balanced but accurate way to increase transparency.

摘要

目的:探讨在早期临床试验中实现多样性的重要性和障碍。

设计:使用主题分析对定性访谈进行分析。

设置和参与者:2022 年 6 月至 8 月期间,对 5 名专业人员(临床研究人员和方法学家)和 3 名患者和公众代表(有早期临床试验经验和/或来自少数民族背景的人员)进行了访谈。参与者是通过他们的机构网页、现有联系人或社交媒体(例如,X,前身为 Twitter)确定的。

结果:专业人员认为多样性目前并未在所有早期临床试验中考虑,但认为应该始终考虑到多样性。这些试验主要在少数几个中心进行,因此限制了他们可以接触到的人群。来自社区的临床医生的转介可能会增加多样性;然而,转介的人往往不是来自服务不足的群体。转介可能会受到向服务不足的群体提出并招募的额外资源的阻碍,而参与者通常不得不进行“自我驱动”的转介。患者和公众代表表示,研究人员的多样性很重要,应该告知潜在参与者多样性的必要性。来自服务不足群体的人可能需要澄清治疗的潜在危害,即使这些危害未知。教育可以提高对早期临床试验的认识和看法。我们提供了 14 条建议,以提高早期临床试验的多样性。

结论:多样性应在所有早期试验中考虑。需要考虑多样性的程度以及如何解决多样性问题。招募服务不足群体所需的额外资源可能需要资助者增加资金,以支持招募这些参与者。应以平衡但准确的方式向潜在参与者介绍研究的潜在危害和社会效益,以提高透明度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34e7/10952868/d621d827ea2c/bmjopen-2023-075547f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34e7/10952868/d621d827ea2c/bmjopen-2023-075547f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34e7/10952868/d621d827ea2c/bmjopen-2023-075547f01.jpg

相似文献

[1]
Exploring the barriers to, and importance of, participant diversity in early-phase clinical trials: an interview-based qualitative study of professionals and patient and public representatives.

BMJ Open. 2024-3-19

[2]
The future of Cochrane Neonatal.

Early Hum Dev. 2020-11

[3]
Perceived Institutional Barriers Among Clinical and Research Professionals: Minority Participation in Oncology Clinical Trials.

JCO Oncol Pract. 2021-5

[4]
Involving South Asian patients in clinical trials.

Health Technol Assess. 2004-10

[5]
Intersecting factors of disadvantage and discrimination and their effect on daily life during the coronavirus pandemic: the CICADA-ME mixed-methods study.

Health Soc Care Deliv Res. 2025-2

[6]
Using digital tools in the recruitment and retention in randomised controlled trials: survey of UK Clinical Trial Units and a qualitative study.

Trials. 2020-4-3

[7]
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

Cochrane Database Syst Rev. 2022-2-1

[8]
"We are not invited": Australian focus group results on how to improve ethnic diversity in trials.

J Clin Epidemiol. 2024-6

[9]
Evaluating a tool to improve engagement and recruitment of under-served groups in trials.

Trials. 2022-10-9

[10]
Identifying barriers to outpatient appointment attendance in patient groups at risk of inequity: a mixed methods study in a London NHS trust.

BMC Health Serv Res. 2024-4-30

引用本文的文献

[1]
Measuring trust in medical research: Perspectives from racial and ethnic communities underrepresented in research.

J Clin Transl Sci. 2025-4-10

[2]
Analysis of 4616 clinical trial initial submissions received by the Medicines and Healthcare products Regulatory Agency between February 2019 and October 2023.

Br J Clin Pharmacol. 2025-9

[3]
Community-Engaged Approaches for Improving the Inclusion of Diverse Communities in a Nutrition Clinical Trial.

Nutrients. 2024-10-23

[4]
Exploring Dietary Salt Knowledge, Attitude, and Practices among People of African Descent in the United Kingdom: A Qualitative Study.

Healthcare (Basel). 2024-10-2

[5]
Patient and public involvement and engagement in the development of innovative patient-centric early phase dose-finding trial designs.

Res Involv Engagem. 2024-6-19

本文引用的文献

[1]
The Importance of Diversity and Inclusion in Drug Development and Clinical Trial Conduct.

J Clin Pharmacol. 2022-12

[2]
COVID-19 Vaccine Hesitancy, Medical Mistrust, and Mattering in Ethnically Diverse Communities.

J Racial Ethn Health Disparities. 2023-6

[3]
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study.

ESMO Open. 2022-6

[4]
Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response.

Br J Clin Pharmacol. 2022-6

[5]
Developing a toolkit for increasing the participation of black, Asian and minority ethnic communities in health and social care research.

BMC Med Res Methodol. 2022-1-14

[6]
Promoting inclusion in clinical trials-a rapid review of the literature and recommendations for action.

Trials. 2021-12-4

[7]
Fair payment and just benefits to enhance diversity in clinical research.

J Clin Transl Sci. 2021-7-14

[8]
Disparities in phase 1 cancer clinical trial enrollment.

Cancer. 2021-12-1

[9]
Improving diversity in research and trial participation: the challenges of language.

Lancet Public Health. 2021-7

[10]
Enrolment of older adults with cancer in early phase clinical trials-an observational study on the experience in the north west of England.

Age Ageing. 2021-9-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索